Robotics
PrivateA dead de-SPAC — ~$190M raised, $0 revenue, zero humans ever treated — now holding a July 21 2026 shareholder vote on its own dissolution with the board itself guiding common to ~$0; the equity is a near-certain zero, not a turnaround.
Research
The verdict
A dead de-SPAC — ~$190M raised, $0 revenue, zero humans ever treated — now holding a July 21 2026 shareholder vote on its own dissolution with the board itself guiding common to ~$0; the equity is a near-certain zero, not a turnaround.
Primary sources
Source documents — open to read in full
Vicarious Surgical is a development-stage medical-robotics company in Waltham, MA, building a single-port surgical robot — the Vicarious Surgical System — that combines miniaturized robotics, computer science, sensing and 3D visualization to "virtually transport surgeons inside the patient" through one ~1.8 cm abdominal incision. The system's pitch: nine degrees of freedom per instrument arm (approximating a surgeon's wrist/elbow/shoulder), 28 sensors per arm for force/motion feedback, and a de-coupled architecture that keeps the robotic motion inside the abdomen rather than in large arms outside the body. First intended indication: ventral hernia repair (the filing cites ~3.9M cases worldwide, ~0.9M U.S. annually), with a claimed longer-run addressable base of ~39–45M soft-tissue abdominal/gynecological procedures.
Business model: there isn't a live one. Revenue = $0; the company "has not yet generated any revenue from operations". The intended model was a razor-and-blade capital-equipment play (sell/place the robot into hospitals and ambulatory surgical centers, then recurring instruments/service), explicitly targeting the ASC cost-sensitive segment as a wedge below Intuitive's hospital footprint. None of it was ever commercialized. Customers: none. Suppliers: third-party custom + off-the-shelf component vendors feeding in-house assembly at Waltham. Competitors: Intuitive Surgical, J&J (Ethicon/Auris/Verb), Medtronic (Covidien/Hugo), Virtual Incision, Stryker, CMR Surgical.
Corporate history is the whole story: went public 17 Sept 2021 via SPAC merger with D8 Holdings at a $1.1B combined valuation, netting the company ~$190.4M of cash (after ~$29.6M transaction costs; PIPE priced at $10.00). Nearly five years later that ~$190M — plus subsequent raises — has become a $253.4M accumulated deficit and a company voting on liquidation. This is a textbook de-SPAC deep-tech capital incineration.
For a pre-commercial company the supply chain is aspirational, and its weakness was a direct cause of death. Map: custom miniaturized components + off-the-shelf parts (third-party vendors) → in-house assembly/manufacturing at the Waltham HQ → (intended) hospitals & ASCs. The company disclosed it "currently rel[ies] and expect[s] to expand on third parties for the manufacturing of certain products for preclinical and clinical testing, as well as for commercial manufacturing". No commercial supply chain was ever stood up — there is no distributor, no OEM, no installed base.
The named chokepoint is procurement of custom miniaturized robotic components: in March 2025 management blamed "material procurement issues with suppliers" for slipping the build-out and pushing first-patient timing. A robot with 28 sensors and nine-DOF miniaturized joints per arm is a bespoke-parts problem; single-source custom components on a cash-starved timeline is exactly the kind of dependency that compounds delay. The commercial-layer robotics files (kb/robotics/wiki/supply-chain.md, bottlenecks.md) frame the category's precision-actuator/sensor sourcing constraint generically; Vicarious never scaled far enough to matter within it. Bottom line: the supply chain is a liability, not a moat — it never existed at commercial scale and its immaturity helped kill the timeline.
On paper the IP story is real: a genuinely differentiated single-incision, nine-DOF, motion-inside-the-body architecture that, if it worked and shipped, would sidestep both multi-port da Vinci's multiple incisions and da Vinci SP's larger single trocar. Founders machined the original system and the patent estate around de-coupled miniaturized actuation is the one arguably durable asset.
But a moat you cannot fund is not a moat. Judged honestly:
The durable truth of surgical robotics is that it is winner-take-most and brutally capital-intensive; a differentiated architecture is necessary but nowhere near sufficient. Vicarious had the architecture and ran out of the capital. Moat verdict: an interesting patent estate with no economic moat around it.
Not applicable in the revenue sense — there are no segments because there is no revenue (segments.csv is empty; revenue = $0). The only meaningful "segment" breakdown is the cost structure, which is where the whole story lives:
| Line ($M) | FY2024 | FY2025 | YoY |
|---|---|---|---|
| Research & development | 40.2 | 33.6 | −16% |
| Total operating expenses | 66.6 | 50.0 | −25% |
| Net loss | (63.2) | (50.2) | improved 21% |
| Net loss / share | (10.74) | (8.19) | — |
Source:. Implied G&A ≈ $16.4M FY2025.
The "improvement" is not operating leverage — it is the sound of a company being dismantled: R&D down because R&D staff were being laid off, opex down because the company was cutting to survive. Q1 2026 net loss was $7.3M vs $15.4M in Q1 2025 — again, shrinkage, not progress. There is no product mix, no geography, no accelerating line. The only trend is contraction toward zero.
With no earnings to beat, the "result" is the cash position and the milestone state. Both are terminal.
Liquidity (the decisive number):
| Metric ($M) | 31 Dec 2025 | 31 Mar 2026 |
|---|---|---|
| Cash & equivalents | 2.57 | 1.41 |
| Short-term investments | 7.22 | 2.28 |
| Total liquidity | 9.79 | 3.68 |
| Accumulated deficit | (246.1) | (253.4) |
| Total assets | 19.6 | 12.6 |
| Total liabilities | 9.7 | 9.0 |
| Total stockholders' equity | 9.8 | 3.57 |
Source:.
Milestone state (the "pipeline"): the Vicarious System is still pre-clinical. As of the FY2025 10-K the company only "plan[s] to conduct a prospective human pivotal clinical investigation under an FDA IDE" and must still complete non-clinical V&V (bench, cadaver, in-vivo animal studies) before it can even submit an IDE, let alone run the pivotal trial and then file the De Novo classification request. Translation: no IDE, no first-in-human, no design freeze. The March 2026 strategic plan still put "system design freeze by the end of 2026" as a future goal — meaning first-in-human, the pivotal trial, and De Novo submission were all still 2027+ events requiring, realistically, $100M+ of fresh capital.
Guidance/outlook: the only guidance that matters is the going-concern disclosure — cash "will be sufficient to support the Company's operations through the second quarter of 2026," raising substantial doubt about going-concern. 2026 cash burn was guided to ~$19M (cut from ~$50M mid-2025 and ~$35M late-2025). Balance-sheet flags: no traditional debt, but ~$5.7M of non-current liabilities (chiefly the Waltham operating lease); public warrants marked to $0 and delisted.
Market reaction / what was priced in: by the time of the print the market had already rendered its verdict — NYSE delisting for a sub-$15M market cap, OTC since 4 March 2026, stock at pennies. Nothing left to be surprised by.
There are no clean earnings-call transcripts on the shelf (transcripts/ empty), but the tonal arc across public commentary is unambiguous and damning:
The recurring phrase they stopped saying was any firm FDA submission date; the phrase they started saying was "going concern." That is the entire sentiment trend you need.
Multiples are meaningless for a $0-revenue dissolving shell, so the comp set is (a) the incumbent that defines the moat wall and (b) the fate of sub-scale challengers:
| Company | Ticker | Status | Valuation / outcome | Note |
|---|---|---|---|---|
| Intuitive Surgical | ISRG | Category king | ~$142.5B mkt cap; ~59x trailing / ~46x fwd P/E; ~50x EV/EBITDA; +21% rev growth Q1'26 | Ships da Vinci SP single-port; 400+ peer-reviewed pubs. The wall Vicarious tried to climb. |
| Asensus Surgical | (was ASXC) | Absorbed | Acquired by Karl Storz at $0.35/share cash, closed 22 Aug 2024, after $20M bridge | The best-case exit for a sub-scale single-port robotics pure-play: a distressed sale at pennies. |
| CMR Surgical | private | Struggling incumbent-challenger | Raised >$1B; "Versius" commercial ex-US | Even the best-funded challenger burns capital relentlessly. |
| Vicarious Surgical | RBOT | Dissolving | Mkt cap ~$1.2M; heading to ABC/dissolution | The worst-case outcome: no acquirer, no residual to equity. |
RBOT price ~$0.16–0.17 as of 2026-07-09. NB: one aggregator shows a $30M market cap — inconsistent with the 7.12M share count at $0.17 ($1.2M) and almost certainly stale/pre-decline; I flag the conflict and rely on the arithmetic. The takeaway is structural: surgical robotics is a category where one $140B incumbent compounds while sub-scale challengers get bought at pennies (Asensus) or dissolve (Vicarious). There is no valuation multiple to argue about — only a liquidation waterfall (Lens 11).
The pattern of >5% moves reveals a market that reacted to exactly one variable: survival.
What the market "reacts to" for this name is not earnings or product — it is each incremental signal of whether the company will run out of money. It has now answered yes.
CEO: Stephen From (62), CEO & director since Aug 2025 — a turnaround/wind-down hire, not a robotics operator. Prior: CEO of Aruna Bio (2022–2025) and Kiora Pharmaceuticals; earlier CFO of Centelion (a Sanofi biotech subsidiary) and investment banking. Bringing in a small-cap biotech restructuring executive in Aug 2025 was, in hindsight, the board signaling that the mission had shifted from build the robot to manage the endgame.
Co-founder Adam Sachs (34) — original CEO, demoted to President when From arrived; still a director. Co-founders Sammy Khalifa (CTO) and Barry Greene built the original system. CFO: Sarah Romano (45).
Accounting-fraud risk: low. Going-concern-realization risk: total. This is not a company cooking books to inflate revenue — there is no revenue to inflate. The forensic risks are the pre-revenue, wind-down kind:
Regulatory findings (required):
There is no EPS to forecast (no revenue, no path to profit, dissolving). The only defensible projection is the recovery to common in the ABC/dissolution. No forecast.ts logged — a Brier EPS forecast is meaningless here (per --watchlist rules, no forecast create).
Waterfall (as of 31 Mar 2026, the balance sheet the proxy relies on):
Why book equity ≈ $3.57M still maps to ~$0 for common: (1) non-cash assets liquidate well below carrying value in an ABC; (2) continued Q2 burn (~$1.5–2M) further drains the $3.68M before the process even completes; (3) ABC/assignee/wind-down professional fees are senior to equity; (4) the lease and accrued liabilities absorb realizable proceeds. Base / Bull / Bear:
The decisive question the +clinical overlay asks — "does cash runway reach the next value-inflection catalyst?" — answers itself: NO, by years and by ~$100M. The runway ran out one full De Novo pathway before the first catalyst.
Bull case (steelmanned, for completeness): A genuinely novel single-port, nine-DOF architecture addressing a 39–45M-procedure TAM, in a category where the one incumbent trades at ~$142B and ~50x EBITDA — i.e., the prize is enormous and the technology is differentiated. If (huge if) an acquirer valued the IP/design and hired the team, the patents could live on inside a Medtronic/J&J/Stryker. But this is an asset bull case, not an equity bull case — and it accrues to creditors and an acquirer, not to RBOT shareholders.
Bear case (the reality): three permanent impairments, all already realized: (1) capital exhaustion — $3.68M against a >$100M path to approval; (2) no market access — delisted to OTC, no ability to raise equity on acceptable terms, explicitly failed to find debt/equity/buyer; (3) terminal governance decision — the board has chosen dissolution over continuing. Pre-mortem (it's 18 months out and the thesis broke): it already broke — the "thesis" died the moment the July 21 vote is cast; there is no 18-month scenario, only a wind-down. Multiples too high? There is no multiple; there is a liquidation. Contrarian view of what the market refuses to see: nothing — for once the market (pennies, delisted) sees this exactly right. The only "refusal to see" would be a retail buyer treating $0.17 as cheap; it is not cheap, it is a claim junior to $9M of liabilities the board says will consume the estate.
As a short-seller there is nothing left to dismantle — the bull case has already been dismantled by the issuer itself. The structural break in how the company "makes money" is that it never did and now never will. Revenue concentration risk is moot (revenue is $0). The moat is weaker than any bull thinks because it was never funded to exist. The most dangerous competitor was never Intuitive — it was the calendar and the cash balance, and both won. The worst capital-allocation move was the entire arc: ~$190M+ of SPAC/PIPE capital spent over ~5 years reaching not even first-in-human. The assumptions that had to hold for the price — continued financing access, a completable design, a reachable FDA path — all failed simultaneously. The single scenario that permanently impairs the business (insolvency) is not a scenario; it is the current, disclosed state. The only short-seller caution is mechanical: at $0.16 and ~$1.2M market cap the borrow is nonexistent and the downside to a hard-zero is only pennies — there is no trade here, long or short; there is only avoidance.
Research Trail
Covered in the Knowledge Base
Robotics & Humanoid Automation
A sub-scale, worst-financials-in-cohort servo maker priced at ~6–7x sales on humanoid-robot optionality that is still immaterial to the P&L — the industrial base is in a margin-destroying price war and drowning in ~200-day PV/lithium receivables; the Q1-2026 near-breakeven is a real inflection, but you are paying a robotics multiple for an automation turnaround. BEARISH on risk/reward, WATCHING for genuine humanoid order conversion + sustained GAAP profit.
The weakest-margin, lowest-ROE member of the robotics Big Four — now the most richly priced of them (51x trailing / 34x forward / 28x EV-EBITDA, dearer than FANUC) after a +139% year, on trough earnings and a 7.8% ROE, while Inovance takes its servo crown at home in China; the Physical-AI / Motoman-NEXT / humanoid story is real optionality but the market has already paid for the entire Dash-35 turnaround and then some, and consensus's own price target sits BELOW spot.